Cognitive decline: The relevance of diabetes, hyperlipidaemia and hypertension

British Journal of Diabetes and Vascular Disease

Volumn 10, Issue 3, 2010, Pages 115-122

  Etgen, Thorleif ^a   Sander, Dirk ^b,c   Bickel, Horst ^a   Sander, Kerstin ^a   Förstl, Hans ^b,c  

^a Klinikum Traunstein   (Germany)

^b Medical Park Loipl ^*  (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cognitive impairment; Dementia; Diabetes; Hyperlipidaemia; Hypertension

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ATENOLOL; ATORVASTATIN; CANDESARTAN; CERIVASTATIN; CHOLESTEROL; ENALAPRIL; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLUCOSE; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; NICOTINIC ACID; NITRENDIPINE; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAVASTATIN; RALOXIFENE; ROSUVASTATIN; SIMVASTATIN;

ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; AUTOPSY; BODY MASS; BRAIN ATHEROSCLEROSIS; BRAIN CIRCULUS ARTERIOSUS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; DEMENTIA; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATIONAL STATUS; FOLLOW UP; GLYCEMIC CONTROL; GOLD STANDARD; HEART DISEASE; HIPPOCAMPUS; HISPANIC; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEUKOARAIOSIS; MEDICARE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL HEALTH; PATHOGENESIS; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SELF REPORT; SMOKING; STROKE; VISUAL IMPAIRMENT;

EID: 77957158667     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651410368408     Document Type: Review

References (59)

1. Gauthier S, Reisberg B, Zaudig M et al. Mild cognitive impairment Lancet 2006;367:1262-70
2. Panza F, D'Introno A, Colacicco AM et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry 2005;13:633-44
3. Luck T, Riedel-heller SG, Kaduszkiewicz H et al. Mild cognitive impair-ment in general practice: age-specific prevalence and correlate results from the german study on ageing, cognition and dementia in primary care patients (AgeCoDe). Dement Geriatr Cogn Disord 2007;24:307-16
4. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive mpairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009;119:252-65
5. Forstl H, Bickel H, Grolich L et al. [MCI-plus: mild cognitive impairment with rapid progression. Part I: prevention and therapy]. Dtsch Med Wochenschr 2009;134:39-44
6. Etgen T, Bronner M, Sander D et al. Somatic factors in cognitive impair-ment. Fortschr Neurol Psychiatr 2009; 77: 72-82.
7. Erkinjuntti T, Gauthier S. The concept of vascular cognitive impairment Front Neurol Neurosci 2009;24:79-85
8. Brownlee M. Biochemistry and molecular cell biology of diabetic com-plications. Nature 2001;414:813-20.
9. Farris W, Mansourian S, Chang Y et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003;100:4162-7
10. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 2005;33:1041-4
11. Den Heijer T, Vermeer SE, Van Dijk EJ et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia. 2003; 46: 1604-10.
12. Biessels GJ, Koffeman A, Scheltens P. Diabetes and cognitive impair-ment. Clinical diagnosis and brain imaging in patients attending a memory clinic. J Neurol 2006;253:477-82
13. Sonnen JA, Larson EB, Brickell K et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch N eurol 2009;66:315-22
14. Strachan MW, Deary IJ, Ewing FM et al. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997;20:438-45
15. Biessels GJ, Staekenborg S, Brunner E et al. Risk of dementia in diabe-tes mellitus: a systematic review. Lancet Neurol 2006;5:64-74
16. Gregg EW, Yaffe K, Cauley JA et al. Is diabetes associated with cogni-tive impairment and cognitive decline among older women? Study of osteoporotic fractures Research group. Arch Intern Med 2000;160:174-80
17. Logroscino G, Kang JH, Grodstein F. Prospective study of type 2 diabe-tes and cognitive decline in women aged 70-81 years. BMJ 2004;328:548
18. Yaffe K, Blackwell T, Kanaya AM et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women Neurology 2004;63:658-63
19. Okereke OI, Kang JH, Cook NR et al. Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults. J Am Geriatr Soc 2008;56:1028-36
20. Luchsinger JA, Reitz C, Patel B et al. Relation of diabetes to mild cogni-tive impairment. Arch Neurol 2007;64:570-5
21. Whitmer RA, Karter AJ, Yaffe K et al. hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565-72.
22. Bruce DG, Davis WA, Casey GP et al. Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the fremantle Diabetes Study. Diabetologia 2009;52:1808-15
23. Hartmann T, Kuchenbecker J, Grimm MO. Alzheimer's disease: the ipid connection. J Neurochem 2007;103(suppl 1):159-70.
24. Pappolla MA, Bryant-Thomas TK, Herbert D et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003;61:199-205.
25. Roher AE, Esh C, Kokjohn TA et al. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 2003;23:2055-62
26. Kivipelto M, Helkala El, Hanninen T et al. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 2001;56:1683-9.
27. Whitmer RA, Sidney S, Selby J et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277-81
28. Dufouil C, Richard F, Fievet N et al. APoe genotype, cholesterol level, ipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005;64:1531-8
29. Solfrizzi V, Panza F, Colacicco AM et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004;63 1882-91
30. Li G, Shofer JB, Kukull WA et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 2005;65:1045-50
31. Reitz C, Tang MX, Luchsinger J et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004;61 705-14
32. Panza F, Capurso C, D'Introno A et al. Total cholesterol levels and the risk of mild cognitive impairment and Alzheimer's disease. J Am Geriatr Soc 2007;55:133-5
33. Wolozin B, Kellman W, Ruosseau P et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coen-zyme A reductase inhibitors. Arch Neurol 2000;57:1439-43
34. Jick H, Zornberg GL, Jick SS et al. Statins and the risk of dementia Lancet 2000;356:1627-31
35. Cramer C, Haan MN, Galea S et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008;71:344-50.
36. Haag MD, Hofman A, Koudstaal PJ et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009;80:13-7
37. Group HPSC. MRC/BHF heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised pla-cebo-controlled trial. Lancet 2002;360:7-22
38. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PRoSPeR): a randomised controlled trial Lancet 2002;360:1623-30
39. Mcguinness B, Craig D, Bullock R et al. Statins for the prevention of dementia. Cochrane Database Syst Rev 2009;(2):CD003160
40. Sparks L. Statins and cognitive function. J Neurol Neurosurg Psychiatry 2009;80:1-2
41. Spence JD. Cerebral consequences of hypertension: where do they lead? J Hypertens Suppl 1996;14:S139-45
42. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4:487-99
43. Hoffman IB, Schmeidler J, Lesser GT et al. less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 2009;72:1720-6
44. Birns J, Kalra L. Cognitive function and hypertension. J Hum Hypertens 2008
45. Prince MJ, Bird AS, Blizard RA et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 1996;312:801-5
46. Forette F, Seux Ml, Staessen JA et al. Prevention of dementia in ran-domised double-blind placebo-controlled Systolic hypertension in europe (Systeur) trial. Lancet 1998;352:1347-51
47. Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic hypertension in europe (Systeur) study. Arch Intern Med 2002;162 2046-52
48. Applegate WB, Pressel S, Wittes J et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 1994;154:2154-60
49. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the elderly (SCoPe): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
50. Tzourio C, Anderson C, Chapman N et al. effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069-75
51. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the hypertension in the Very elderly Trial cognitive function assessment (hYVeT-Cog): a double-blind, placebo controlled trial. Lancet Neurol 2008;7:683-9
52. Mcguinness B, Todd S, Passmore P et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cogni-tive impairment and dementia. Cochrane Database Syst Rev 2009;(4):CD004034
53. Poon IO. effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 2008;28 366-75
54. Takeda S, Sato N, Takeuchi D et al. Angiotensin receptor blocker pre-vented β-amyloid-induced cognitive impairment associated with recov-ery of neurovascular coupling. Hypertension 2009;54:1345-52
55. Sink KM, Leng X, Williamson J et al. Angiotensin-converting enzyme nhibitors and cognitive decline in older adults with hypertension results from the cardiovascular health study. Arch Intern Med 2009;169:1195-202
56. Birns J, Markus H, Kalra L. Blood pressure reduction for vascular risk: is there a price to be paid? Stroke 2005;36:1308-13
57. Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged sword. Ageing Res Rev 2009;8:61-70.
58. Haag MD, Hofman A, Koudstaal PJ et al. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology 2009;72:1727-34
59. Skoog I, Lernfelt B, Landahl S et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5